vs

Side-by-side financial comparison of COHEN & STEERS, INC. (CNS) and CORCEPT THERAPEUTICS INC (CORT). Click either name above to swap in a different company.

CORCEPT THERAPEUTICS INC is the larger business by last-quarter revenue ($202.1M vs $143.8M, roughly 1.4× COHEN & STEERS, INC.). COHEN & STEERS, INC. runs the higher net margin — 24.3% vs 12.0%, a 12.2% gap on every dollar of revenue. On growth, CORCEPT THERAPEUTICS INC posted the faster year-over-year revenue change (11.1% vs 2.9%). CORCEPT THERAPEUTICS INC produced more free cash flow last quarter ($38.4M vs $-126.4M). Over the past eight quarters, CORCEPT THERAPEUTICS INC's revenue compounded faster (17.3% CAGR vs 8.3%).

Cohen & Steers is an American investment management company. It focuses on investments in real estate securities via real estate investment trusts (REIT) and alternative income via preferred securities.

Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD.

CNS vs CORT — Head-to-Head

Bigger by revenue
CORT
CORT
1.4× larger
CORT
$202.1M
$143.8M
CNS
Growing faster (revenue YoY)
CORT
CORT
+8.2% gap
CORT
11.1%
2.9%
CNS
Higher net margin
CNS
CNS
12.2% more per $
CNS
24.3%
12.0%
CORT
More free cash flow
CORT
CORT
$164.8M more FCF
CORT
$38.4M
$-126.4M
CNS
Faster 2-yr revenue CAGR
CORT
CORT
Annualised
CORT
17.3%
8.3%
CNS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CNS
CNS
CORT
CORT
Revenue
$143.8M
$202.1M
Net Profit
$34.9M
$24.3M
Gross Margin
98.7%
Operating Margin
28.0%
2.2%
Net Margin
24.3%
12.0%
Revenue YoY
2.9%
11.1%
Net Profit YoY
-23.9%
-21.0%
EPS (diluted)
$0.67
$0.20

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CNS
CNS
CORT
CORT
Q4 25
$143.8M
$202.1M
Q3 25
$141.7M
$207.6M
Q2 25
$136.1M
$194.4M
Q1 25
$134.5M
$157.2M
Q4 24
$139.8M
$181.9M
Q3 24
$133.2M
$182.5M
Q2 24
$121.7M
$163.8M
Q1 24
$122.7M
$146.8M
Net Profit
CNS
CNS
CORT
CORT
Q4 25
$34.9M
$24.3M
Q3 25
$41.7M
$19.7M
Q2 25
$36.8M
$35.1M
Q1 25
$39.8M
$20.5M
Q4 24
$45.8M
$30.7M
Q3 24
$39.7M
$47.2M
Q2 24
$31.8M
$35.5M
Q1 24
$34.0M
$27.8M
Gross Margin
CNS
CNS
CORT
CORT
Q4 25
98.7%
Q3 25
97.8%
Q2 25
98.2%
Q1 25
98.5%
Q4 24
98.4%
Q3 24
98.4%
Q2 24
98.5%
Q1 24
98.3%
Operating Margin
CNS
CNS
CORT
CORT
Q4 25
28.0%
2.2%
Q3 25
34.5%
4.9%
Q2 25
31.8%
13.7%
Q1 25
33.6%
2.2%
Q4 24
35.3%
13.9%
Q3 24
33.7%
25.5%
Q2 24
31.5%
21.7%
Q1 24
32.8%
20.1%
Net Margin
CNS
CNS
CORT
CORT
Q4 25
24.3%
12.0%
Q3 25
29.4%
9.5%
Q2 25
27.1%
18.1%
Q1 25
29.6%
13.1%
Q4 24
32.8%
16.9%
Q3 24
29.8%
25.9%
Q2 24
26.1%
21.7%
Q1 24
27.7%
18.9%
EPS (diluted)
CNS
CNS
CORT
CORT
Q4 25
$0.67
$0.20
Q3 25
$0.81
$0.16
Q2 25
$0.72
$0.29
Q1 25
$0.77
$0.17
Q4 24
$0.89
$0.25
Q3 24
$0.77
$0.41
Q2 24
$0.63
$0.32
Q1 24
$0.68
$0.25

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CNS
CNS
CORT
CORT
Cash + ST InvestmentsLiquidity on hand
$145.5M
$372.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$562.0M
$647.8M
Total Assets
$876.7M
$836.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CNS
CNS
CORT
CORT
Q4 25
$145.5M
$372.2M
Q3 25
$98.1M
$421.7M
Q2 25
$95.4M
$342.2M
Q1 25
$65.2M
$322.8M
Q4 24
$183.0M
$383.3M
Q3 24
$106.5M
$380.3M
Q2 24
$122.0M
$473.2M
Q1 24
$99.5M
$410.8M
Stockholders' Equity
CNS
CNS
CORT
CORT
Q4 25
$562.0M
$647.8M
Q3 25
$550.3M
$631.9M
Q2 25
$528.5M
$635.8M
Q1 25
$507.7M
$683.3M
Q4 24
$511.7M
$679.6M
Q3 24
$491.0M
$638.8M
Q2 24
$463.2M
$596.2M
Q1 24
$378.9M
$547.9M
Total Assets
CNS
CNS
CORT
CORT
Q4 25
$876.7M
$836.7M
Q3 25
$801.6M
$823.6M
Q2 25
$751.0M
$801.7M
Q1 25
$834.9M
$846.5M
Q4 24
$812.4M
$840.6M
Q3 24
$727.8M
$784.3M
Q2 24
$784.1M
$714.6M
Q1 24
$680.7M
$655.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CNS
CNS
CORT
CORT
Operating Cash FlowLast quarter
$-120.4M
$38.4M
Free Cash FlowOCF − Capex
$-126.4M
$38.4M
FCF MarginFCF / Revenue
-87.9%
19.0%
Capex IntensityCapex / Revenue
4.2%
0.0%
Cash ConversionOCF / Net Profit
-3.45×
1.58×
TTM Free Cash FlowTrailing 4 quarters
$-253.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CNS
CNS
CORT
CORT
Q4 25
$-120.4M
$38.4M
Q3 25
$55.1M
$54.5M
Q2 25
$-67.6M
$43.9M
Q1 25
$-108.9M
$5.1M
Q4 24
$96.7M
$59.3M
Q3 24
$25.6M
$73.8M
Q2 24
$31.4M
$41.2M
Q1 24
$4.9M
$23.8M
Free Cash Flow
CNS
CNS
CORT
CORT
Q4 25
$-126.4M
$38.4M
Q3 25
$52.6M
Q2 25
$-69.8M
$43.9M
Q1 25
$-110.0M
$5.0M
Q4 24
$85.0M
$59.2M
Q3 24
$24.2M
$72.2M
Q2 24
$27.1M
$40.8M
Q1 24
$537.0K
FCF Margin
CNS
CNS
CORT
CORT
Q4 25
-87.9%
19.0%
Q3 25
37.1%
Q2 25
-51.3%
22.6%
Q1 25
-81.8%
3.2%
Q4 24
60.8%
32.5%
Q3 24
18.2%
39.5%
Q2 24
22.3%
24.9%
Q1 24
0.4%
Capex Intensity
CNS
CNS
CORT
CORT
Q4 25
4.2%
0.0%
Q3 25
1.8%
0.0%
Q2 25
1.6%
0.0%
Q1 25
0.8%
0.1%
Q4 24
8.3%
0.1%
Q3 24
1.1%
0.9%
Q2 24
3.5%
0.3%
Q1 24
3.5%
0.0%
Cash Conversion
CNS
CNS
CORT
CORT
Q4 25
-3.45×
1.58×
Q3 25
1.32×
2.77×
Q2 25
-1.84×
1.25×
Q1 25
-2.74×
0.25×
Q4 24
2.11×
1.93×
Q3 24
0.65×
1.56×
Q2 24
0.99×
1.16×
Q1 24
0.14×
0.86×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons